CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Newsroom
April 23, 2024
![Read Now Button](/sites/default/files/2024-04/sidebar-newsletter.jpg)
January 18, 2024
![Newsletter logo](/sites/default/files/2024-02/Untitled%20design%20-%202024-02-14T132141.717_0.png)
December 27, 2023
![AstraZeneca Logo](/sites/default/files/2023-12/logo-az.png)
December 21, 2023
US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life
Additional regulatory reviews underway in rest of world